A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

Cardiovascular Diabetology

Volumn 16, Issue 1, 2017, Pages

  Gantz, Ira ^a   Chen, Menghui ^a   Suryawanshi, Shailaja ^a   Ntabadde, Catherine ^a   Shah, Sukrut ^a   O'Neill, Edward A ^a   Engel, Samuel S ^a   Kaufman, Keith D ^a   Lai, Eseng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antihyperglycemic agent; Dipeptidyl peptidase 4; Incretin; MK 3102

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; AMYLASE; ASPARTATE AMINOTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HUMALOG 75/25; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; NOVOLOG 70/30; OMARIGLIPTIN; PIG INSULIN; PIOGLITAZONE; PLACEBO; RECOMBINANT HUMAN INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; 2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)-2,6-DIHYDROPYRROLO(3,4-C)PYRAZOL-5(4H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; PYRAN DERIVATIVE;

ACUTE PANCREATITIS; ADULT; ADVERSE OUTCOME; AMYLASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; ASYMPTOMATIC DISEASE; BLOOD PRESSURE; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FATALITY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PARALLEL DESIGN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PYRANS; RISK FACTORS;

EID: 85029218795     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0593-8     Document Type: Article

References (15)

1. Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014;57:3205-12.
2. Goldenberg R, Gantz I, Andryuk PJ, O'Neill EA, Kaufman KD, Lai E, et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2017;19:394-400.
3. Gantz I, Okamoto T, Ito Y, Okuyama K, O'Neill EA, Kaufman KD, et al. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017. doi: 10.1111/dom.12988.
4. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-42.
5. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35.
6. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
7. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067-76.
8. Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, et al. Pancreatic safety of sitagliptin in the TECOS study. Diabetes Care. 2017;40:164-70.
9. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, et al. Standardized definitions for cardiovascular and stroke end point events in clinical trials. https://pdfs.semanticscholar.org/efab/995c2062926101c1c28224e10b9732b47b59.pdf?_ga=2.236088453.524366300.1496402363-1295595830.14964023632014. Accessed 02 June 2017.
10. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-35.
11. U.S. Food and Drug Administration. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. https://www.fda.gov/downloads/Drugs/./guidances/UCM174090.pdf. Accessed 02 June 2017.
12. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28:1352-61.
13. Moses RG, Round E, Shentu Y, Golm GT, O'Neill EA, Gantz I, et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016;8:701-11.
14. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733-45.
15. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med. 2014;370:794-7.